NCT03158805.

Study name	Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder
Methods	A Randomised, Placebo‐Controlled Study of Liraglutide 3 mg Daily (Saxenda®)
Participants	Obese or overweight patients with stable bipolar disorder. Participants will have a DSM‐5 bipolar disorder that is clinically stable and will be obese (defined as BMI ≥ 30 mg/kg²) or overweight (defined as BMI ≥ 27 kg/m²) with at least 1 weight‐related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia
Interventions	Liraglutide 3 mg daily (Saxenda®) vs placebo
Outcomes	Primary outcome: percent change in body weight over 2 years
Starting date	April 2017
Contact information	Susan McElroy, Chief Research Officer Lindner Center of HOPE
Notes